Formulating and developing effective transdermal products has always proven to be a complex and difficult task. By offering a combination of development and direct manufacture, Greene Street is well positioned to benefit the lives of patients and physicians. With Transdermal Innovative Products (TiPs®) currently scheduled for animal studies and human clinical trials, Greene Street is able to unleash it's sizable pipeline for license.
comparative oral drug specifications
to meet the current FDA rules and guidelines
the majority of GI side effects from oral drugs
delivery for patients with swallowing diffculties
Greene Street has a laser focus on identifying impactful products, the formulation of TiPs®, and the creation of robust product development processes that can be scaled effectively for our partners.
Greene Street also offers a full range of manufacturing capabilities, with a focus on the manufacture of all transdermal supplies for clinical studies, registration batches for regulatory approvals and even commercialization.
Product Formulation, In-house Development, and Support of Regulatory Filings and Manufacturing blend seamlessly at Greene Street, enabling us to offer you a full spectrum of Transdermal Innovative Products.
All TiPs® have been developed and tested in our labs and scheduled for animal studies and human clinical trials. Our portfolio is extensive, expanding rapidly and available immediately for license.